A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Silmitasertib (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Senhwa Biosciences
- 05 Sep 2018 Planned number of patients changed from 209 to 216.
- 05 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Nov 2021.
- 05 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2021.